Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials

ANNALS OF ONCOLOGY

ELSEVIER

1. Merck KGaA, Darmstadt, Germany
2. GlaxoSmithKline